These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17981755)

  • 1. Rationally-designed vaccine adjuvants: separating efficacy from toxicity.
    Hauguel TM; Hackett CJ
    Front Biosci; 2008 Jan; 13():2806-13. PubMed ID: 17981755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic vaccines: the role of adjuvants in immune targeting.
    Jiang ZH; Koganty RR
    Curr Med Chem; 2003 Aug; 10(15):1423-39. PubMed ID: 12871139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll or toll-free adjuvant path toward the optimal vaccine development.
    Ishii KJ; Akira S
    J Clin Immunol; 2007 Jul; 27(4):363-71. PubMed ID: 17370119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvants and autoimmunity.
    Israeli E; Agmon-Levin N; Blank M; Shoenfeld Y
    Lupus; 2009 Nov; 18(13):1217-25. PubMed ID: 19880572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of defined TLR ligands as adjuvants within human vaccines.
    Duthie MS; Windish HP; Fox CB; Reed SG
    Immunol Rev; 2011 Jan; 239(1):178-96. PubMed ID: 21198672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of adjuvants for immunotherapy.
    Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor Ligands.
    Xu Z; Moyle PM
    Bioconjug Chem; 2018 Mar; 29(3):572-586. PubMed ID: 28891637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the Microparticle Nanoscale Silicon Dioxide as an Adjuvant To Boost Vaccine Immune Responses against Influenza Virus in Neonatal Mice.
    Russell RF; McDonald JU; Lambert L; Tregoning JS
    J Virol; 2016 May; 90(9):4735-4744. PubMed ID: 26912628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Syk-Card9-activating C-type lectin receptors by vaccine adjuvants: findings, implications and open questions.
    Lang R; Schoenen H; Desel C
    Immunobiology; 2011 Nov; 216(11):1184-91. PubMed ID: 21742403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune adjuvants in early life: targeting the innate immune system to overcome impaired adaptive response.
    de Brito CA; Goldoni AL; Sato MN
    Immunotherapy; 2009 Sep; 1(5):883-95. PubMed ID: 20636030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG in Combination with an Inhibitor of Notch Signaling Suppresses Formalin-Inactivated Respiratory Syncytial Virus-Enhanced Airway Hyperresponsiveness and Inflammation by Inhibiting Th17 Memory Responses and Promoting Tissue-Resident Memory Cells in Lungs.
    Zhang L; Li H; Hai Y; Yin W; Li W; Zheng B; Du X; Li N; Zhang Z; Deng Y; Zeng R; Wei L
    J Virol; 2017 May; 91(10):. PubMed ID: 28275186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity.
    Marciani DJ
    Drug Discov Today; 2003 Oct; 8(20):934-43. PubMed ID: 14554157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvants may reduce in vivo transfection levels for DNA vaccination in mice leading to reduced antigen-specific CD8+ T cell responses.
    Rose AH; Hoffmann FW; Hara JH; Urschitz J; Moisyadi S; Hoffmann PR; Bertino P
    Hum Vaccin Immunother; 2015; 11(9):2305-11. PubMed ID: 26091088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human innate responses and adjuvant activity of TLR ligands in vivo in mice reconstituted with a human immune system.
    Cheng L; Zhang Z; Li G; Li F; Wang L; Zhang L; Zurawski SM; Zurawski G; Levy Y; Su L
    Vaccine; 2017 Oct; 35(45):6143-6153. PubMed ID: 28958808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STING pathway stimulation results in a differentially activated innate immune phenotype associated with low nitric oxide and enhanced antibody titers in young and aged mice.
    Darling RJ; Senapati S; Kelly SM; Kohut ML; Narasimhan B; Wannemuehler MJ
    Vaccine; 2019 May; 37(20):2721-2730. PubMed ID: 30987850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine adjuvants: putting innate immunity to work.
    Coffman RL; Sher A; Seder RA
    Immunity; 2010 Oct; 33(4):492-503. PubMed ID: 21029960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvants containing natural and synthetic Toll-like receptor 4 ligands.
    Ireton GC; Reed SG
    Expert Rev Vaccines; 2013 Jul; 12(7):793-807. PubMed ID: 23885824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The path forward.
    De Gregorio E
    Vaccine; 2015 Jun; 33 Suppl 2():B60-3. PubMed ID: 26022572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.